RALOXIFENE HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Raloxifene Hydrochloride, and when can generic versions of Raloxifene Hydrochloride launch?
Raloxifene Hydrochloride is a drug marketed by Amneal Pharms, Aurobindo Pharma, Cadila Pharms Ltd, Glenmark Pharms Ltd, Invagen Pharms, Sciegen Pharms Inc, Teva Pharms Usa, and Watson Labs Inc. and is included in eight NDAs.
The generic ingredient in RALOXIFENE HYDROCHLORIDE is raloxifene hydrochloride. There are seventeen drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the raloxifene hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Raloxifene Hydrochloride
A generic version of RALOXIFENE HYDROCHLORIDE was approved as raloxifene hydrochloride by TEVA PHARMS USA on March 4th, 2014.
Summary for RALOXIFENE HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 8 |
NDAs: | 8 |
Finished Product Suppliers / Packagers: | 16 |
Raw Ingredient (Bulk) Api Vendors: | 117 |
Clinical Trials: | 85 |
Patent Applications: | 3,488 |
Formulation / Manufacturing: | see details |
DailyMed Link: | RALOXIFENE HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for RALOXIFENE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
German University in Cairo | Phase 2 |
Cairo University | Phase 2 |
University of Houston | N/A |
Pharmacology for RALOXIFENE HYDROCHLORIDE
Drug Class | Estrogen Agonist/Antagonist |
Mechanism of Action | Selective Estrogen Receptor Modulators |